Ephrin-A3 (EFNA3) is a member of the ephrin family, a group of cell surface-bound ligands that interact with Eph receptors, the largest family of receptor tyrosine kinases. EFNA3 is a glycosylphosphatidylinositol (GPI)-anchored protein primarily involved in bidirectional cell-cell signaling, regulating processes such as cell adhesion, migration, and tissue boundary formation. It plays critical roles in developmental biology, including angiogenesis, neural development, and immune system regulation. Dysregulation of EFNA3 has been implicated in pathological conditions, such as cancer progression, vascular abnormalities, and inflammatory diseases.
EFNA3 antibodies are immunological tools designed to detect, quantify, or modulate EFNA3 protein expression and function. These antibodies are widely used in research to study EFNA3's role in signaling pathways, its interaction with Eph receptors (e.g., EphA4), and its impact on cellular behaviors in vitro and in vivo. Applications include immunohistochemistry, Western blotting, flow cytometry, and functional assays to explore EFNA3's contribution to tumor microenvironment remodeling, metastasis, or therapeutic resistance. Some antibodies are also explored for therapeutic potential, aiming to block EFNA3-Eph receptor interactions in diseases like cancer. Specificity and validation (e.g., knockout controls) are critical, as EFNA3 shares structural homology with other ephrins. Commercial antibodies vary in clonality, epitope recognition, and species reactivity, tailored for diverse experimental needs.